FY2027 EPS Estimates for IceCure Medical Lowered by Analyst

IceCure Medical Ltd (NASDAQ:ICCM) – Equities research analysts at Brookline Capital Management reduced their FY2027 earnings estimates for IceCure Medical in a research note issued to investors on Thursday, March 27th. Brookline Capital Management analyst K. Dolliver now expects that the company will post earnings of $0.22 per share for the year, down from their prior forecast of $0.23. The consensus estimate for IceCure Medical’s current full-year earnings is ($0.28) per share. Brookline Capital Management also issued estimates for IceCure Medical’s FY2028 earnings at $0.32 EPS and FY2029 earnings at $0.42 EPS.

Separately, HC Wainwright reissued a “buy” rating and issued a $2.50 target price on shares of IceCure Medical in a report on Friday.

IceCure Medical Stock Up 0.5 %

IceCure Medical stock opened at $1.11 on Monday. The stock’s 50 day moving average price is $1.32 and its 200 day moving average price is $0.99. IceCure Medical has a 1-year low of $0.48 and a 1-year high of $1.66. The company has a market cap of $61.61 million, a PE ratio of -3.83 and a beta of 0.37. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.67 and a quick ratio of 2.27.

IceCure Medical (NASDAQ:ICCM) last announced its quarterly earnings data on Thursday, March 27th. The company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). The business had revenue of $1.07 million during the quarter, compared to analysts’ expectations of $1.07 million. IceCure Medical had a negative net margin of 376.85% and a negative return on equity of 124.44%.

Institutional Inflows and Outflows

An institutional investor recently raised its position in IceCure Medical stock. Geode Capital Management LLC lifted its position in shares of IceCure Medical Ltd (NASDAQ:ICCM) by 58.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 40,453 shares of the company’s stock after acquiring an additional 14,893 shares during the quarter. Geode Capital Management LLC owned 0.07% of IceCure Medical worth $44,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 0.62% of the company’s stock.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.